Therapeutic siRNA: state of the art

RNA interference (RNAi) is an ancient biological mechanism used to defend against external invasion. It theoretically can silence any disease-related genes in a sequence-specific manner, making small interfering RNA (siRNA) a promising therapeutic modality. After a two-decade journey from its discovery, two approvals of siRNA therapeutics, ONPATTRO ® (patisiran) and GIVLAARI™ (givosiran), have been achieved by Alnylam Pharmaceuticals. Reviewing the long-term pharmaceutical history of human beings, siRNA therapy currently has set up an extraordinary milestone, as it has already changed and will continue to change the treatment and management of human diseases. It can be administered quarterly, even twice-yearly, to achieve therapeutic effects, which is not the case for small molecules and antibodies. The drug development process was extremely hard, aiming to surmount complex obstacles, such as how to efficiently and safely deliver siRNAs to desired tissues and cells and how to enhance the performance of siRNAs with respect to their activity, stability, specificity and potential off-target effects. In this review, the evolution of siRNA chemical modifications and their biomedical performance are comprehensively reviewed. All clinically explored and commercialized siRNA delivery platforms, including the GalNAc ( N -acetylgalactosamine)–siRNA conjugate, and their fundamental design principles are thoroughly discussed. The latest progress in siRNA therapeutic development is also summarized. This review provides a comprehensive view and roadmap for general readers working in the field.

[1]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[2]  H. Bonkovsky,et al.  Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria , 2019, The New England journal of medicine.

[3]  Zicai Liang,et al.  Pharmacokinetic Behaviors of Intravenously Administered siRNA in Glandular Tissues , 2016, Theranostics.

[4]  R. Spizzo,et al.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. , 2013, Cancer discovery.

[5]  Yu-cheng Tseng,et al.  Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[6]  M. Burnier,et al.  Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury , 2017, Kidney international reports.

[7]  D. Kornbrust,et al.  Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. , 2014, Nucleic acid therapeutics.

[8]  Wenyu Li,et al.  Identification of metabolically stable 5′-phosphate analogs that support single-stranded siRNA activity , 2015, Nucleic acids research.

[9]  Ryan L Setten,et al.  The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.

[10]  Shuling Guo,et al.  Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice , 2014, Nucleic acids research.

[11]  Rob Lambkin-Williams,et al.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus , 2010, Proceedings of the National Academy of Sciences.

[12]  Xiaoqi Liu.  Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment , 2015, Translational oncology.

[13]  Elisa Franco,et al.  Programmable RNA microstructures for coordinated delivery of siRNAs. , 2016, Nanoscale.

[14]  A. Fisher,et al.  Click Modification of RNA at Adenosine: Structure and Reactivity of 7-Ethynyl- and 7-Triazolyl-8-aza-7-deazaadenosine in RNA , 2014, ACS chemical biology.

[15]  J. Wengel,et al.  Stopped-flow kinetics of locked nucleic acid (LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions. , 2001, The Biochemical journal.

[16]  J. Moreno-Montañés,et al.  Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  E. Galun,et al.  A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma. , 2013 .

[18]  Yuanyu Huang,et al.  RNAi therapeutic and its innovative biotechnological evolution. , 2019, Biotechnology advances.

[19]  K. Ye,et al.  Single modification at position 14 of siRNA strand abolishes its gene‐silencing activity by decreasing both RISC loading and target degradation , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  R. Eliakim,et al.  RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients , 2015, Oncotarget.

[21]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[22]  P. Nielsen,et al.  Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication , 2017, Molecular therapy. Nucleic acids.

[23]  D. Hwang,et al.  Delivery of High Mobility Group Box-1 siRNA Using Brain-Targeting Exosomes for Ischemic Stroke Therapy. , 2019, Journal of biomedical nanotechnology.

[24]  Yuanyu Huang,et al.  Clinical advances of siRNA therapeutics , 2019, The journal of gene medicine.

[25]  Junji Kato,et al.  Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone , 2008, Nature Biotechnology.

[26]  Zicai Liang,et al.  pH-Sensitive Nanomicelles for High-Efficiency siRNA Delivery in Vitro and in Vivo: An Insight into the Design of Polycations with Robust Cytosolic Release. , 2016, Nano letters.

[27]  Zicai Liang,et al.  Site-Specific Modification Using the 2′-Methoxyethyl Group Improves the Specificity and Activity of siRNAs , 2017, Molecular therapy. Nucleic acids.

[28]  T. D. de Witte,et al.  siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. , 2010, Blood.

[29]  T. Suda,et al.  Mitochondria Transfer from Hematopoietic Stem and Progenitor Cells to Pdgfrα+/Sca-1-/CD48dim BM Stromal Cells Via CX43 Gap Junctions and AMPK Signaling Inversely Regulate ROS Generation in Both Cell Populations , 2016 .

[30]  Kai Liu,et al.  Simultaneous silencing of TGF-β1 and COX-2 reduces human skin hypertrophic scar through activation of fibroblast apoptosis , 2017, Oncotarget.

[31]  Zhihong Li,et al.  Efficient delivery of nucleic acid molecules into skin by combined use of microneedle roller and flexible interdigitated electroporation array , 2018, Theranostics.

[32]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  N. Snead,et al.  Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model. , 2019, ACS infectious diseases.

[34]  R. Yu,et al.  Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 , 2007, Drug Metabolism and Disposition.

[35]  M. Manoharan,et al.  siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2 , 2016, Nucleic acids research.

[36]  P. Low,et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.

[37]  G. Abou-Alfa,et al.  An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma , 2018, The oncologist.

[38]  B. Bettencourt,et al.  Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study , 2015, Orphanet Journal of Rare Diseases.

[39]  K. G. Rajeev,et al.  Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates , 2017, Nucleic acids research.

[40]  B. Molitoris,et al.  siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. , 2009, Journal of the American Society of Nephrology : JASN.

[41]  Yuanyu Huang,et al.  The challenge and prospect of mRNA therapeutics landscape. , 2020, Biotechnology advances.

[42]  T. P. Prakash,et al.  Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues. , 2010, The Journal of organic chemistry.

[43]  Sabrina Pricl,et al.  A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy. , 2018, Journal of the American Chemical Society.

[44]  M. Büchler,et al.  Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. , 2004, European journal of cancer.

[45]  H. Harashima,et al.  A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Guping Tang,et al.  A supramolecular co-delivery strategy for combined breast cancer treatment and metastasis prevention , 2020 .

[47]  H. Bonkovsky,et al.  GS-14-ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients , 2019, Journal of Hepatology.

[48]  K. Giese,et al.  Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. , 2012, International journal of clinical pharmacology and therapeutics.

[49]  Yajnavalka Banerjee,et al.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. , 2017, The New England journal of medicine.

[50]  Qiao Jiang,et al.  Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. , 2010, ACS nano.

[51]  J. Ambati,et al.  Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth , 2009, Proceedings of the National Academy of Sciences.

[52]  Shu-ichi Matsuzawa,et al.  Lipid Nanoparticle-mediated siRNA Transfer Against PCTAIRE1/PCTK1/Cdk16 Inhibits In Vivo Cancer Growth , 2016, Molecular therapy. Nucleic acids.

[53]  F. Szoka,et al.  Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. , 2001, Cancer research.

[54]  Y. Kopelman,et al.  Mutant KRAS is a druggable target for pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[55]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[56]  Y. Ramot,et al.  Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy , 2016, Toxicologic pathology.

[57]  C. Croce,et al.  RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model , 2015, Oncotarget.

[58]  Ji-Ho Park,et al.  Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery , 2019, Advanced materials.

[59]  M. Zamora,et al.  RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. , 2011, American journal of respiratory and critical care medicine.

[60]  J. Pelletier,et al.  Phenylpyrrolocytosine as an unobtrusive base modification for monitoring activity and cellular trafficking of siRNA. , 2011, ACS chemical biology.

[61]  Ravi Braich,et al.  Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide. , 2006, ACS chemical biology.

[62]  Min Wu,et al.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects , 2020, Signal Transduction and Targeted Therapy.

[63]  Peixuan Guo,et al.  Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA , 2015, Scientific Reports.

[64]  Yang Liu,et al.  A reactive oxygen species-responsive dendrimer with low cytotoxicity for efficient and targeted gene delivery , 2020 .

[65]  Yechezkel Barenholz,et al.  Multistep, effective drug distribution within solid tumors , 2015, Oncotarget.

[66]  Xing-jie Liang,et al.  Effects of hydrophobic core components in amphiphilic PDMAEMA nanoparticles on siRNA delivery. , 2015, Biomaterials.

[67]  P. Campochiaro,et al.  Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 , 2006, Gene Therapy.

[68]  Vladimir P Torchilin,et al.  Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. , 2006, Annual review of biomedical engineering.

[69]  B. Wiedenmann,et al.  Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. , 2008, Cancer research.

[70]  anastasia. khvorova,et al.  The chemical evolution of oligonucleotide therapies of clinical utility , 2017, Nature Biotechnology.

[71]  Peixuan Guo,et al.  Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[72]  D. Lewis,et al.  Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes. , 2015, Methods in molecular biology.

[73]  C. Napoli,et al.  Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. , 1990, The Plant cell.

[74]  W. Flanagan,et al.  Modeling the Kinetics of Lipid-Nanoparticle- Mediated Delivery of Multiple siRNAs to Evaluate the Effect on Competition for Ago2 , 2019, Molecular therapy. Nucleic acids.

[75]  O. Schwardt,et al.  Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. , 2008, Bioorganic & medicinal chemistry.

[76]  S. Crooke,et al.  Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages , 2022 .

[77]  U. Kavita,et al.  Safety, tolerability, and pharmacokinetics of BMS-986263/ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: A randomised, placebo-controlled, double-blind, phase 1 study , 2018 .

[78]  Stanley T Crooke,et al.  Cellular uptake and trafficking of antisense oligonucleotides , 2017, Nature Biotechnology.

[79]  A. Pavlícek,et al.  Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial , 2017, The Lancet.

[80]  Peixuan Guo,et al.  Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression , 2018, Redox biology.

[81]  S. Kanner,et al.  RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg , 2017, Science Translational Medicine.

[82]  Yang Li,et al.  A Flow-Through Cell Electroporation Device for Rapidly and Efficiently Transfecting Massive Amounts of Cells in vitro and ex vivo , 2016, Scientific Reports.

[83]  C. Burrows,et al.  Chemical modification of siRNA bases to probe and enhance RNA interference. , 2011, The Journal of organic chemistry.

[84]  R. Falk,et al.  Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis , 2015, Orphanet Journal of Rare Diseases.

[85]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[86]  B. Molitoris,et al.  Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. , 2012, Nucleic acid therapeutics.

[87]  Peixuan Guo,et al.  Nanoparticle Orientation to Control RNA Loading and Ligand Display on Extracellular Vesicles for Cancer Regression , 2017, Nature Nanotechnology.

[88]  A. Akinc,et al.  Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy , 2017, The New England journal of medicine.

[89]  J. Lieberman,et al.  Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.

[90]  S. Duenwald,et al.  Lipid nanoparticle purification by spin centrifugation-dialysis (SCD): a facile and high-throughput approach for small scale preparation of siRNA-lipid complexes. , 2011, International journal of pharmaceutics.

[91]  S. Ashley,et al.  EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma , 2004, Oncogene.

[92]  Zicai Liang,et al.  Modification of the siRNA Passenger Strand by 5‐Nitroindole Dramatically Reduces its Off‐Target Effects , 2012, Chembiochem : a European journal of chemical biology.

[93]  V. Goel,et al.  Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria , 2020, Clinical pharmacology and therapeutics.

[94]  Darren H. Wakefield,et al.  Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes , 2007, Proceedings of the National Academy of Sciences.

[95]  P. Kaiser,et al.  VEGF inhibitors for the treatment of neovascular age-related macular degeneration. , 2009, Expert opinion on investigational drugs.

[96]  L. Cekaite,et al.  Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. , 2007, Biochemical and biophysical research communications.

[97]  K. Giese,et al.  First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  Creagh,et al.  A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B , 2016 .

[99]  H. Tian,et al.  Preparation of poly(glutamic acid) shielding micelles self-assembled from polylysine-b-polyphenylalanine for gene and drug codelivery , 2020 .

[100]  Robert Langer,et al.  Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity , 2014, Nature Communications.

[101]  K. G. Rajeev,et al.  Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[102]  Mark E. Davis.  The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[103]  F. Szoka,et al.  Mechanism of oligonucleotide release from cationic liposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[104]  P. Beal,et al.  Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs. , 2010, ACS chemical biology.

[105]  C. Bennett.  Therapeutic Antisense Oligonucleotides Are Coming of Age. , 2019, Annual review of medicine.

[106]  M. Jung,et al.  Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides , 2017, Molecular therapy. Nucleic acids.

[107]  Robert Langer,et al.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.

[108]  S. Elbashir,et al.  Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). , 2008, Antiviral research.

[109]  S. Ganesh,et al.  RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[110]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[111]  E. Ohtsuka,et al.  Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides. , 1987, Nucleic acids research.

[112]  D. Rozema.  The Chemistry of Oligonucleotide Delivery , 2017 .

[113]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[114]  R. Epand,et al.  Inhibition of protein kinase C by cationic amphiphiles. , 1992, Biochemistry.

[115]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[116]  B. Bettencourt,et al.  ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[117]  Xing-jie Liang,et al.  Systemic Administration of siRNA via cRGD-containing Peptide , 2015, Scientific Reports.

[118]  L. Neckers,et al.  Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. , 1995, Antisense research and development.

[119]  Naoki Iwamoto,et al.  Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides , 2017, Nature Biotechnology.

[120]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[121]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[122]  M. Ammirati,et al.  Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor. , 2017, Journal of the American Chemical Society.

[123]  F. Muñoz-Negrete,et al.  Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease. , 2016, Investigative ophthalmology & visual science.

[124]  M. V. González,et al.  In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[125]  P. Triozzi,et al.  Phase I clinical trial of adoptive cellular immunotherapy with APN401 in patients with solid tumors , 2015, Journal of Immunotherapy for Cancer.

[126]  J. Moreno-Montañés,et al.  Tivanisiran, a novel siRNA for the treatment of dry eye disease , 2018, Expert opinion on investigational drugs.

[127]  E. Cherkaev,et al.  Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA , 2017, Molecular therapy. Nucleic acids.

[128]  D. Lewis,et al.  Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers , 2016, Clinical pharmacology in drug development.

[129]  M. Gottesman,et al.  In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. , 2002, Human gene therapy.

[130]  Chen Gao,et al.  Effective Gene Silencing Mediated by Polypeptide Nanoparticles LAH4-L1-siMDR1 in Multi-Drug Resistant Human Breast Cancer. , 2019, Journal of biomedical nanotechnology.

[131]  G. Verdine.  Drugging the "undruggable". , 2006, Harvey lectures.

[132]  Judy Lieberman,et al.  Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown , 2015, Nature Biotechnology.

[133]  J. R. Vargas,et al.  Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: basic science, research tools, and clinical applications. , 2013, Accounts of chemical research.

[134]  Christopher E. Hart,et al.  Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index , 2019, Nature Biotechnology.

[135]  J. Kjems,et al.  A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects , 2010, Nucleic acids research.

[136]  S. Milstein,et al.  Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[137]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[138]  Mark E. Davis,et al.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer , 2015, Nature Reviews Drug Discovery.

[139]  B. Jessen,et al.  Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[140]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[141]  Yang Wang,et al.  Adaptive amphiphilic dendrimer-based nanoassemblies as robust and versatile siRNA delivery systems. , 2014, Angewandte Chemie.

[142]  R. Gish,et al.  A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population , 2017 .

[143]  F. Baas,et al.  The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence. , 2009, Methods in molecular biology.

[144]  N. Nishiyama,et al.  Enhanced stability and gene silencing ability of siRNA-loaded polyion complexes formulated from polyaspartamide derivatives with a repetitive array of amino groups in the side chain. , 2012, Biomaterials.

[145]  Kit S Lam,et al.  Tumor-targeting peptides from combinatorial libraries. , 2017, Advanced drug delivery reviews.

[146]  S. Crooke,et al.  Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins , 2019, Nucleic acids research.

[147]  M. Yuen,et al.  Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. , 2015, Antiviral research.

[148]  M. Hassan.  FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors , 2017, Global cardiology science & practice.

[149]  S. Milstein,et al.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia , 2015, Nature Medicine.

[150]  A. Khvorova.  Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. , 2017, The New England journal of medicine.

[151]  N. Žarković,et al.  Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. , 2006, Cancer letters.

[152]  P. Haslett,et al.  An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. , 2017, Journal of the American Society of Nephrology : JASN.

[153]  X. Anguela,et al.  Entering the Modern Era of Gene Therapy. , 2019, Annual review of medicine.

[154]  M. Boffa,et al.  New Frontiers in Lp(a)-Targeted Therapies. , 2019, Trends in pharmacological sciences.

[155]  O. Farokhzad,et al.  Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy. , 2020, Nano letters.

[156]  A. Khvorova,et al.  Improving siRNA Delivery In Vivo Through Lipid Conjugation. , 2018, Nucleic acid therapeutics.

[157]  Jeong-Woo Choi,et al.  Application of peptide nucleic acid towards development of nanobiosensor arrays. , 2010, Bioelectrochemistry.

[158]  Zicai Liang,et al.  Elimination pathways of systemically delivered siRNA. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[159]  S. Crooke,et al.  RNA-Targeted Therapeutics. , 2018, Cell metabolism.

[160]  C. Ghiciuc,et al.  NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY. , 2016, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[161]  Wei Wang,et al.  An efficient and high-throughput electroporation microchip applicable for siRNA delivery. , 2011, Lab on a chip.

[162]  A. Khvorova,et al.  Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo , 2018, bioRxiv.

[163]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[164]  S. Pluchino,et al.  RNA Nanotherapeutics for the Amelioration of Astroglial Reactivity , 2017, Molecular therapy. Nucleic acids.

[165]  M. Abrams,et al.  Recent preclinical and clinical advances in oligonucleotide conjugates , 2018, Expert opinion on drug delivery.

[166]  Wei Tao,et al.  ROS‐Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy , 2019, Advanced materials.

[167]  Yan Deng,et al.  Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-carriers , 2014, Theranostics.

[168]  Darren H. Wakefield,et al.  Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. , 2012, Nucleic acid therapeutics.

[169]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[170]  A. Jackson,et al.  A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. , 2019, The Journal of investigative dermatology.

[171]  K. Giese,et al.  Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[172]  Zhihong Li,et al.  Transdermal Delivery of Nucleic Acid Mediated by Punching and Electroporation. , 2020, Methods in molecular biology.

[173]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[174]  D. Corey,et al.  Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs , 2017, Nucleic acids research.

[175]  Zhiyuan Hu,et al.  A Pliable Electroporation Patch (ep-Patch) for Efficient Delivery of Nucleic Acid Molecules into Animal Tissues with Irregular Surface Shapes , 2015, Scientific Reports.

[176]  Xing-jie Liang,et al.  Ternary complexes of amphiphilic polycaprolactone-graft-poly (N,N-dimethylaminoethyl methacrylate), DNA and polyglutamic acid-graft-poly(ethylene glycol) for gene delivery. , 2011, Biomaterials.

[177]  Ling Peng,et al.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[178]  K. G. Rajeev,et al.  Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates , 2019, Nucleic acids research.

[179]  M. Haas.  Alnylam interrupts preeclampsia , 2014 .

[180]  Zhiming M. Wang,et al.  Recent Progress in the Fabrication, Properties, and Devices of Heterostructures Based on 2D Materials , 2019, Nano-micro letters.

[181]  Jihye Hwang,et al.  Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. , 2016, The Journal of investigative dermatology.

[182]  J. Summerton,et al.  Morpholino antisense oligomers: design, preparation, and properties. , 1997, Antisense & nucleic acid drug development.

[183]  Alan McLachlan,et al.  Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[184]  Chad A. Mirkin,et al.  Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma , 2013, Science Translational Medicine.

[185]  Priti Kumar,et al.  Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[186]  Svetlana Shulga Morskaya,et al.  RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy , 2009, Antimicrobial Agents and Chemotherapy.

[187]  A. Di Polo,et al.  Ocular neuroprotection by siRNA targeting caspase-2 , 2011, Cell Death and Disease.

[188]  A. Khvorova,et al.  5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo , 2017, Nucleic acids research.

[189]  Yingliang Wu,et al.  A Tat-conjugated Peptide Nucleic Acid Tat-PNA-DR Inhibits Hepatitis B Virus Replication In Vitro and In Vivo by Targeting LTR Direct Repeats of HBV RNA , 2016, Molecular therapy. Nucleic acids.

[190]  D. Adams,et al.  Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis , 2019, Revue Neurologique.

[191]  Wei Wang,et al.  A laminar flow electroporation system for efficient DNA and siRNA delivery. , 2011, Analytical chemistry.

[192]  B. Bettencourt,et al.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial , 2014, The Lancet.

[193]  R. Hickerson,et al.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[194]  Javier Martinez,et al.  The human RNA kinase hClp1 is active on 3′ transfer RNA exons and short interfering RNAs , 2007, Nature.

[195]  H. Dudek,et al.  Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin , 2016, Molecular Cancer Therapeutics.

[196]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[197]  H. Dolstra,et al.  siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice , 2015, Cancer Immunology, Immunotherapy.

[198]  Peixuan Guo,et al.  Advancement of the Emerging Field of RNA Nanotechnology , 2017, ACS nano.

[199]  T. Seufferlein,et al.  A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma. , 2016 .

[200]  M. Caruthers,et al.  Phosphorodithioate DNA as a potential therapeutic drug. , 1993, Science.

[201]  J. Young,et al.  Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo , 2018, Molecular therapy. Nucleic acids.

[202]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[203]  N. Nishiyama,et al.  Functional polymer‐based siRNA delivery carrier that recognizes site‐specific biosignals , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[204]  A. Turner,et al.  Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. , 2018, Journal of hepatology.

[205]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[206]  S. Crooke,et al.  Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells. , 2019, Nucleic acid therapeutics.

[207]  Darren H. Wakefield,et al.  Protease-triggered siRNA delivery vehicles. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[208]  Zhihong Li,et al.  Continuous Vector-free Gene Transfer with a Novel Microfluidic Chip and Nanoneedle Array. , 2018, Current drug delivery.

[209]  A. Khvorova,et al.  The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[210]  Yuanyu Huang,et al.  siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin , 2018, Molecular therapy. Nucleic acids.

[211]  Zicai Liang,et al.  Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo. , 2013, Nanoscale.

[212]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[213]  Eetu Mäkelä,et al.  Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. , 2004, The Journal of clinical investigation.

[214]  Yan-fen Fang,et al.  Targeting NEK2 as a promising therapeutic approach for cancer treatment , 2016, Cell cycle.

[215]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[216]  A. Feldstein,et al.  Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. , 2016, Journal of Hepatology.

[217]  R. Titze-de-Almeida,et al.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market , 2017, Pharmaceutical Research.

[218]  Akin Akinc,et al.  Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles , 2013, Molecular therapy. Nucleic acids.

[219]  M. Damha,et al.  Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid (FANA) , 2006, Nucleic acids research.

[220]  Xing-jie Liang,et al.  Systemic and tumor-targeted delivery of siRNA by cyclic NGR and isoDGR motif-containing peptides. , 2016, Biomaterials science.

[221]  D. Weissman,et al.  Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L , 2011, Nucleic acids research.

[222]  Dan Peer,et al.  Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. , 2015, ACS nano.

[223]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[224]  R. Fucini,et al.  Adenosine modification may be preferred for reducing siRNA immune stimulation. , 2012, Nucleic acid therapeutics.

[225]  A. Brenner,et al.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.

[226]  M. DiFiglia,et al.  Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in Mouse Brain. , 2017, Bioconjugate chemistry.

[227]  Xing-jie Liang,et al.  Fluorinated Oligoethylenimine Nanoassemblies for Efficient siRNA-Mediated Gene Silencing in Serum-Containing Media by Effective Endosomal Escape. , 2018, Nano letters.

[228]  K. G. Rajeev,et al.  Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity , 2018, Nature Communications.

[229]  J. Bennett,et al.  Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. , 2003, Molecular vision.

[230]  Akiko Eguchi,et al.  Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications , 2014, Nature Biotechnology.

[231]  S. Crooke,et al.  Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides , 2020, Nucleic acids research.

[232]  Qiang Zhang,et al.  Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes , 2019, Nature Communications.

[233]  Zicai Liang,et al.  Binary and ternary complexes based on polycaprolactone-graft-poly (N, N-dimethylaminoethyl methacrylate) for targeted siRNA delivery. , 2012, Biomaterials.

[234]  Zicai Liang,et al.  The pH-Triggered Triblock Nanocarrier Enabled Highly Efficient siRNA Delivery for Cancer Therapy , 2017, Theranostics.

[235]  Zicai Liang,et al.  Structural contributions of blocked or grafted poly(2-dimethylaminoethyl methacrylate) on PEGylated polycaprolactone nanoparticles in siRNA delivery. , 2011, Biomaterials.

[236]  A. Jackson,et al.  A synthetic microRNA‐92a inhibitor (MRG‐110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds , 2018, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[237]  M. Egholm,et al.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.

[238]  S. Ganesh,et al.  RNAi-mediated beta-catenin inhibition to promote T-cell infiltration and antitumor activity in combination with immune checkpoint blockade. , 2017 .

[239]  Yongfeng Jiang,et al.  Impact of Oligonucleotide Structure, Chemistry, and Delivery Method on In Vitro Cytotoxicity. , 2017, Nucleic acid therapeutics.

[240]  P. Cullis,et al.  On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids , 2001, Gene Therapy.

[241]  D. Bailey,et al.  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.

[242]  Yuxuan Zheng,et al.  Base Modification Strategies to Modulate Immune Stimulation by an siRNA , 2015, Chembiochem : a European journal of chemical biology.

[243]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[244]  Peixuan Guo,et al.  Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy. , 2018, Cancer letters.

[245]  Stanley T. Crooke,et al.  Single-Stranded siRNAs Activate RNAi in Animals , 2012, Cell.

[246]  George A. Calin,et al.  RNAi Therapies: Drugging the Undruggable , 2014, Science Translational Medicine.

[247]  C. Leumann,et al.  Synthesis and Thermodynamic and Biophysical Properties of Tricyclo-DNA , 1999 .

[248]  Robert Langer,et al.  Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.

[249]  Yuanyu Huang,et al.  Bioinspired exosome-like therapeutics and delivery nanoplatforms. , 2020, Biomaterials.

[250]  Dan Peer,et al.  Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. , 2014, Nanoscale.

[251]  N. Snead,et al.  ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. , 2018, ACS infectious diseases.

[252]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[253]  Abid Qureshi,et al.  siRNAmod: A database of experimentally validated chemically modified siRNAs , 2016, Scientific Reports.

[254]  Guoying Yu,et al.  MicroRNA mimicry blocks pulmonary fibrosis , 2014, EMBO molecular medicine.

[255]  J. Watts,et al.  Chemically modified siRNA: tools and applications. , 2008, Drug discovery today.

[256]  D. S. Houston,et al.  Coronary artery bypass surgery in a patient with Haemophilia A: a case report , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[257]  P. Beal,et al.  7-Substituted 8-aza-7-deazaadenosines for modification of the siRNA major groove. , 2012, Organic & biomolecular chemistry.

[258]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[259]  X. Ji,et al.  Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin to Drug-Resistant Cancer Cells , 2019, Nano-micro letters.

[260]  Martin R. Gill,et al.  Targeted radionuclide therapy in combined-modality regimens. , 2017, The Lancet. Oncology.

[261]  F. Rigo,et al.  Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates , 2019, Nucleic acids research.

[262]  John Durkin,et al.  Tools and applications , 2002 .

[263]  N. Svrzikapa,et al.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.

[264]  A. Jackson,et al.  Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma , 2018, British journal of haematology.

[265]  P. Cullis,et al.  Lipid nanoparticle delivery systems for siRNA-based therapeutics , 2013, Drug Delivery and Translational Research.

[266]  W. Gmeiner,et al.  Development of modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity , 2013, Nucleic acids research.

[267]  Richard G. Lee,et al.  Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle , 2019, Nucleic acids research.

[268]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[269]  L. Marinucci,et al.  Molecular basis of primary hyperoxaluria: clues to innovative treatments , 2018, Urolithiasis.

[270]  K. G. Rajeev,et al.  5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates , 2016, Chembiochem : a European journal of chemical biology.

[271]  A. Willingham,et al.  siRNA-optimized Modifications for Enhanced In Vivo Activity , 2012, Molecular therapy. Nucleic acids.

[272]  F. Szoka,et al.  Mechanism of lipoplex gene delivery in mouse lung: binding and internalization of fluorescent lipid and DNA components , 2001, Gene Therapy.

[273]  A. Borodovsky,et al.  A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH , 2016 .

[274]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[275]  R. Titze-de-Almeida,et al.  Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran , 2019, Molecular Diagnosis & Therapy.

[276]  R. Kimura,et al.  Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity , 2009, Proteins.

[277]  Yuanyu Huang.  Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics , 2016, Molecular therapy. Nucleic acids.

[278]  R. Krauss,et al.  Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference[S] , 2019, Journal of Lipid Research.

[279]  Jie Yu,et al.  Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology , 2019, Molecular therapy. Nucleic acids.